The AlphaLISA™ SureFire® Ultra™ Human Total Progesterone Receptor assay is a sandwich immunoassay for quantitative detection of total Progesterone Receptor in cellular lysates using Alpha Technology.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Protein Quantification |
The AlphaLISA™ SureFire® Ultra™ Human Total Progesterone Receptor assay is a sandwich immunoassay for quantitative detection of total Progesterone Receptor in cellular lysates using Alpha Technology.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
The Progesterone Receptor (PR) is a nuclear hormone receptor activated by the steroid hormone progesterone. PR regulates gene expression involved in reproductive tissue function, cellular differentiation, and proliferation. It exists in two isoforms, PR-A and PR-B, each with distinct and sometimes opposing roles in gene regulation. PR is a critical player in breast cancer development and is a target for endocrine therapies.
The AlphaLISA SureFire Ultra Human Total Progesterone Receptor Detection Kit is a sandwich immunoassay for the quantitative detection of total Progesterone Receptor in cellular lysates, using Alpha Technology.
Formats:
AlphaLISA SureFire Ultra kits are compatible with:
Alpha SureFire Ultra kits can be used for:
Application |
Protein Quantification
|
---|---|
Automation Compatible |
Yes
|
Brand |
AlphaLISA SureFire Ultra
|
Detection Modality |
Alpha
|
Host Species |
Human
|
Molecular Modification |
Total
|
Product Group |
Kit
|
Shipping Conditions |
Shipped in Blue Ice
|
Target |
Progesterone Receptor
|
Target Class |
Phosphoproteins
|
Target Species |
Human
|
Technology |
Alpha
|
Therapeutic Area |
Oncology
|
Unit Size |
500 Assay Points
|
The Total-AlphaLISA SureFire Ultra assay measures the expression level of a protein target in a cell lysate.
The Total-AlphaLISA SureFire Ultra assay uses two antibodies which recognize two different distal epitopes on the targeted protein. AlphaLISA assays require two bead types: Acceptor and Donor beads. Acceptor beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure™ tag. Donor beads are coated with streptavidin to capture one of the detection antibodies, which is biotinylated. In the presence of targeted protein, the two antibodies bring the Donor and Acceptor beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor bead, allowing the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.
The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Ultra detection reagents. This protocol permits the cells' viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.
Detection of Total target protein with AlphaLISA SureFire Ultra reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining AlphaLISA SureFire Ultra quality.
MCF7 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were treated with 0.78 µM of 17-ß Estradiol for 24 hours.
After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Progesterone Receptor Phospho (Ser190) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, treatment with 17-ß Estradiol caused an increase in both Phospho (Ser190) and Total Progesterone Receptor levels.
MCF7 cells were seeded in a 96-well plate (20,000 cells/well) in complete medium, and incubated for 48 hours at 37°C, 5% CO2. The cells were treated with 1 µM of Promegestone for 2 hours. After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Progesterone Receptor Phospho (Ser190) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays.
For the detection step, 10 µL of cell lysate (approximately 2,000 cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, treatment with Promegestone, a well published progesterone receptor agonist, caused an increase in both Phospho (Ser190) and Total Progesterone Receptor levels.
MCF7 cells were seeded in a 96-well plate (40,000 cells/well) in complete medium, and incubated overnight at 37°C, 5% CO2. The cells were treated with 10 µg/mL Fulvestrant for 18 hours. After treatment, the cells were lysed with 100 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). Progesterone Receptor Phospho (Ser190) and Total levels were evaluated using respective AlphaLISA SureFire Ultra assays.
For the detection step, 10 µL of cell lysate (approximately 4,000 cells) were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, Fulvestrant triggered a decrease of both Phospho (Ser190) and Total Progesterone Receptor while Total Cofilin levels remained unchanged (data not shown).
Human cell lysates were diluted with Lysis Buffer. Approximate number of cells/datapoint is indicated on graph.
Total Progesterone Receptor levels were evaluated using the AlphaLISA SureFire Ultra assay. For the detection step, 10 µL of cell lysate were transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor Mix and incubated for 1 hour at RT. Finally, 5 µL of Donor Mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
High levels of Total Progesterone Receptor were detected in breast cancer cell lines, MCF7 and BT-474, expression levels were also found in K-562 and BT-20 cell lines.
Are you looking for resources, click on the resource type to explore further.
We are here to answer your questions.